Compugen reported a Q1 2026 net loss of $7.7 million with approximately $134.9 million in cash, expecting runway into 2029. The COM701 MAIA-ovarian trial is enrolling across the U.S., Israel, and France, with interim analysis expected by Q1 2027. Partner AstraZeneca is advancing rilvegostomig across 11 Phase 3 trials.
Single-cell RNA sequencing of nearly 92,000 cells from the DESTINY-Gastric06 trial reveals distinct primary and acquired resistance mechanisms to trastuzumab deruxtecan in HER2-positive gastric cancer, including MUC3A and CST3 as key drivers.
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07685704 |
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT06846996 |
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China |
RECRUITING | |
| NCT06764875 |
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer |
RECRUITING | PHASE3 |
| NCT05955833 |
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study |
COMPLETED | NA |
| NCT05514717 |
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 |
TERMINATED | PHASE1 |
